Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 132
Selected: 0
NCT IDTitle
NCT02643043UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch
NCT01485874Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
NCT03317158Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT00537173Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT00216073Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
NCT03737123Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT00216203Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
NCT05251038Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
NCT00319735Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT01074970PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
NCT05956041Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
NCT07185945Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT06392841Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
NCT05928806Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT05498272Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT03041181Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT01624493BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
NCT03448718Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
NCT02499952Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
NCT05852717Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT00216086Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
NCT06248606Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
NCT00216099Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
NCT02582749Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
NCT00859339Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
NCT00367601Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
NCT05406713Pembrolizumab in Muscle-invasive Bladder Cancer
NCT03035630Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
NCT06493019Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT03272217Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT03557918Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT01736917Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT04289779Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT02382406Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
NCT04858256Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
NCT02101385Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
NCT00417248Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
NCT00317200A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT00216021Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
NCT06503614A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT00890955Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
NCT06794229Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
NCT03909334Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00216164Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma